The round was led by Oriza Seed Venture Capital, which was joined by TF Capital.
Founded in August 2013 at Suzhou Industrial Park by Dr. Gang Qin, CEO, GeneQuantum has built-up a bio-conjugation technology platform, focusing on developing series of anti-tumor Antibody-Drug-Conjugates (ADCs).
The company intends to use the funds to promote the development of current ADC candidates towards IND filling in both US and China, meanwhile further expanding its product pipeline.
FinSMEs
28/03/2017